Rocketvax News
The next-generation live-attenuated vaccine, named OTS-228, has demonstrated significant safety and efficacy in pre-clinical studies, marking a hopeful advancement in the fight against COVID-19. Developed by researchers from Institute of Virology and Immunology (IVI) Bern, Switzerland and the Friedrich-Loeffler-Institute on the Isle of Riems, Germany on behalf of the Swiss biotech company Rocketvax AG a subsidiary of Swiss Rockets AG, this next-generation vaccine aims to provide enhanced protection against emerging SARS-CoV-2 variants and reduce transmission.
Read the Full News on the RocketVax Website
Read the Corresponding Publication in Nature Microbiology (Open Access)
Figure from Schön, Barut, Trüeb et al (2024) Nat Microbiol published under a CC BY 4.0 license.